Catalog No.: PC-35323Not For Human Use, Lab Use Only.
JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM).
JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM).
JMS-17-2 effectively blocks FKN-induced ERK phosphorylation, also significantly reduces the migration of breast cancer cells in vitro.
JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells, shows long-term anti-tumor effects in vivo.
